Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

Publication | Closed Access

DOI

278

Citations

References

2021

Year

Huabin Hu, Liang Kang, Jianwei Zhang, Zehua Wu, Hui Wang, Meijin Huang, Ping Lan, Xiaojian Wu, Chao Wang, Wuteng Cao,

The Lancet. Gastroenterology & hepatology

Neoadjuvant Pd-1 BlockadeMedicineImmunologyColorectal CancerPathologyMismatch Repair-deficientImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation Oncology